Search Result

Results for "

CC

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CCR (13) ADC Cytotoxin (8) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (16) Autophagy (2) Bacterial (3) Btk (2) CDK (1) ClpP (1) Complement System (1) CXCR (1) Dengue virus (2) DNA Alkylator/Crosslinker (3) DNA-PK (2) DNA/RNA Synthesis (7) DYRK (1) E1/E2/E3 Enzyme (3) E3 Ligase Ligand-Linker Conjugates (2) EBV (1) Endogenous Metabolite (1) Enterovirus (1) Epigenetic Reader Domain (1) ERK (1) Flavivirus (2) Fungal (1) HBV (1) HCV (4) HCV Protease (1) Histone Demethylase (3) HIV (24) Influenza Virus (6) Integrin (1) Interleukin Related (2) Isotope-Labeled Compounds (5) JNK (4) Ligands for E3 Ligase (15) Ligands for Target Protein for PROTAC (1) Liposome (1) LRRK2 (1) MAPKAPK2 (MK2) (1) MMP (1) Molecular Glues (14) mTOR (5) NF-κB (1) Nucleoside Antimetabolite/Analog (1) Parasite (10) Phosphodiesterase (PDE) (3) PI5P4K (1) PKC (1) PPAR (1) PROTAC-Linker Conjugates for PAC (1) PROTACs (1) Proteasome (1) PSMA (1) REV-ERB (1) Reverse Transcriptase (1) RSV (3) SARS-CoV (8) Small Interfering RNA (siRNA) (6) TNF Receptor (2) Virus Protease (1)
By Research Areas:	Cancer (63) Endocrinology (7) Infection (61) Inflammation/Immunology (41) Metabolic Disease (1) Neurological Disease (3)
Click Chemistry:	Azide (1)

163

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

155

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: CCR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13022

CC-401 hydrochloride

5 Publications Verification

CC401 HCl
JNK Cancer

CC-401 hydrochloride is a potent inhibitor of all three forms of JNK with K_i of 25 to 50 nM.

CC-401 hydrochloride 5 Publications Verification CC401 HCl	JNK	Cancer
CC-401 hydrochloride is a potent inhibitor of all three forms of JNK with K_i of 25 to 50 nM.

HY-P99172

CC-90002	Interleukin Related	Cancer
CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar K_d value. CC-90002 can be used for the research of hematologic malignancies and solid tumors .

HY-101488

CC-885 10+ Cited Publications	Molecular Glues Ligands for E3 Ligase	Cancer
CC-885 is a cereblon (CRBN) modulator with potent anti-tumour activity. CC-885 is also a known degrader of GSPT1, inhibiting protein translation.

HY-163064

CC-3240

LRRK2 Cancer

CC-3240 (compound 13) is a molecular glue degrader of CaMKK2 based on CC-8977, with the IC₅₀ of 9 nM .

CC-3240	LRRK2	Cancer
CC-3240 (compound 13) is a molecular glue degrader of CaMKK2 based on CC-8977, with the IC₅₀ of 9 nM .

HY-153698

CC-3060	Ligands for E3 Ligase	Cancer
CC-3060 is a Cereblon modulator that promotes ZBTB16 degradation. CC-3060 degrades ZBTB16 with a DC₅₀ of 0.47 nM in HT-1080 cells. CC-3060 targets ZBTB16 for degradation by primarily engaging distinct structural degrons on different zinc finger domains .

HY-138304

CC-90001 1 Publications Verification	JNK	Inflammation/Immunology
CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK). CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis .

HY-132304

CC-90005	PKC	Inflammation/Immunology
CC-90005 is a potent, selective and orally active inhibitor of protein kinase C-θ (PKC-θ), with an IC₅₀ of 8 nM. CC-90005 shows selectivity for PKC-θ over PKC-δ (IC₅₀=4440 nM). CC-90005 can inhibit T cell activation by inhibiting IL-2 expression .

HY-16962

CC-115 1 Publications Verification	DNA-PK mTOR	Cancer
CC-115 is a potent and dual DNA-PK and mTOR kinase inhibitor with IC₅₀s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.

HY-16962A

CC-115 hydrochloride 1 Publications Verification	DNA-PK mTOR	Cancer
CC-115 hydrochloride is a potent and dual DNA-PK and mTOR kinase inhibitor with IC₅₀s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.

HY-137573

Trotabresib 1 Publications Verification CC-90010	Epigenetic Reader Domain	Cancer
CC-90010 (compound 1) is a reversible and orally active BET inhibitor. CC-90010 is applied in the study for advanced solid tumors .

HY-145931

CC214-2	mTOR Autophagy	Cancer
CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo .

HY-154910

CC214-1	mTOR	Cancer
CC214-1 is a potentially efficacious mTOR inhibitor that induces autophagy ,with an IC₅₀ is 0.002 μM. CC214-1 proved to be useful as an in vitro tool compound for the exploration of mTOR kinase biology. CC214-1 can be used for Glioblastoma study .

HY-112570

CC-90003

1 Publications Verification

ERK Cancer

CC-90003 is an irreversible and selective inhibitor of ERK 1/2 with antitumor activity.
HY-13022A

CC-401

JNK Cancer

CC-401 is a potent inhibitor of all three forms of JNK with K_i of 25 to 50 nM.

CC-90003 1 Publications Verification	ERK	Cancer
CC-90003 is an irreversible and selective inhibitor of ERK 1/2 with antitumor activity.

CC-401	JNK	Cancer
CC-401 is a potent inhibitor of all three forms of JNK with K_i of 25 to 50 nM.

HY-A0003

Lenalidomide Maximum Cited Publications 32 Publications Verification CC-5013	Ligands for E3 Ligase Molecular Glues Apoptosis	Inflammation/Immunology Cancer
Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells .

HY-A0003B

Lenalidomide hemihydrate Maximum Cited Publications 32 Publications Verification CC-5013 hemihydrate	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer
Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator. Lenalidomide hemihydrate (CC-5013 hemihydrate) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hemihydrate (CC-5013 hemihydrate) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells .

HY-A0003A

Lenalidomide hydrochloride CC-5013 hydrochloride	Ligands for E3 Ligase Molecular Glues	Inflammation/Immunology Cancer
Lenalidomide hydrochloride (CC-5013 hydrochloride), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hydrochloride is an orally active immunomodulator. Lenalidomide hydrochloride (CC-5013 hydrochloride) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hydrochloride (CC-5013 hydrochloride) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells .

HY-15495

Tanzisertib

5+ Cited Publications

CC-930
JNK Inflammation/Immunology

Tanzisertib (CC-930) is a potent JNK1/2/3 inhibitor with IC₅₀s of 61/7/6 nM, respectively.

Tanzisertib 5+ Cited Publications CC-930	JNK	Inflammation/Immunology
Tanzisertib (CC-930) is a potent JNK1/2/3 inhibitor with IC₅₀s of 61/7/6 nM, respectively.

HY-139188

CC260	PI5P4K	Metabolic Disease Cancer
CC260 is a selective PI5P4Kα and PI5P4Kβ inhibitor with K_is of 40 nM and 30 nM, respectively. CC260 does not inhibit or weakly inhibits other protein kinases, such as Plk1 and RSK2. CC260 can be used for cell energy metabolism, diabetes and cancer research .

HY-108709

CC-671 1 Publications Verification	CDK	Cancer
CC-671 is a dual TTK protein kinase/CDC2-like kinase (CLK2) inhibitor with IC₅₀s of 0.005 and 0.006 μM for TTK and CLK2, respectively.

HY-123215

CC-17369 7-Hydroxy pomalidomide; Pomalidomide metabolite M16	Ligands for E3 Ligase	Cancer
CC-17369 (7-Hydroxy pomalidomide) is a metabolite of Pomalidomide. CC-17369 is the Pomalidomide -based cereblon (CRBN) ligand used in the recruitment of CRBN protein. CC-17369 can be connected to the ligand for protein by a linker to form PROTAC .

HY-15301

CC0651	E1/E2/E3 Enzyme	Cancer
CC0651 is an allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. CC0651 potently (IC₅₀=1.72 μM) inhibits the ubiquitination of p27 ^Kip1, as confirmed by dose-response analysis.

HY-129388B

Pulrodemstat benzenesulfonate 2 Publications Verification CC-90011 benzenesulfonate; LSD1-IN-7 benzenesulfonate	Histone Demethylase	Cancer
CC-90011 benzenesulfonate is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC₅₀ of 0.25 nM. CC-90011 benzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. CC-90011 benzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .

HY-18012

Spebrutinib

10+ Cited Publications

AVL-292; CC-292
Btk Cancer

Spebrutinib (AVL-292; CC-292) is a covalent, orally active, and highly selective with an IC₅₀ of 0.5 nM.

Spebrutinib 10+ Cited Publications AVL-292; CC-292	Btk	Cancer
Spebrutinib (AVL-292; CC-292) is a covalent, orally active, and highly selective with an IC₅₀ of 0.5 nM.

HY-129395

Mezigdomide CC-92480	E1/E2/E3 Enzyme Molecular Glues Apoptosis	Cancer
Mezigdomide (CC-92480), a cereblon E3 ubiquitin ligase modulating agent (CELMoD), acts as a molecular glue. Mezigdomide shows high affinity to cereblon, resulting in potent antimyeloma activity .

HY-12085

Apremilast 5+ Cited Publications CC-10004	Phosphodiesterase (PDE) Apoptosis TNF Receptor	Inflammation/Immunology
Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM .

HY-147263

Dovramilast CC-11050	Phosphodiesterase (PDE)	Infection Inflammation/Immunology
Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (INH)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB) .

HY-101291

Iberdomide 5+ Cited Publications CC-220	Ligands for E3 Ligase Apoptosis Molecular Glues	Inflammation/Immunology Cancer
Iberdomide (CC-220) is an orally active and potent cereblon (CRBN) E3 ligase modulator (CELMoD) with an IC₅₀ of ~150 nM for cereblon-binding affinity. Iberdomide, a derivative of Thalidomide (HY-14658), has antitumor and immunostimulatory activities .

HY-146237

Golcadomide CC-99282	Ligands for E3 Ligase Molecular Glues	Cancer
Golcadomide (CC-99282) is a potent and orally active cereblon (CRBN) E3 ligase modulator (CELMoD). Golcadomide co-opts CRBN to induce potent and targeted degradation of Ikaros and Aiolos. Golcadomide can be used for researching non-Hodgkin lymphomas .

HY-16956

Onatasertib 2 Publications Verification CC-223; ATG-008	mTOR Apoptosis	Cancer
Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, with an IC₅₀ value for mTOR kinase of 16 nM. Onatasertib inhibits both mTORC1 and mTORC2.

HY-130800

Eragidomide 1 Publications Verification CC-90009	Ligands for E3 Ligase Molecular Glues Apoptosis	Inflammation/Immunology Cancer
Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue. Eragidomide coopts the CRL4 ^CRBN to selectively target GSPT1 for ubiquitination and proteasomal degradation .

HY-129388

Pulrodemstat Methylbenzenesulfonate CC-90011 Methylbenzenesulfonate; LSD1-IN-7 Methylbenzenesulfonate	Histone Demethylase	Cancer
CC-90011 Methylbenzenesulfonate is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC₅₀ of 0.25 nM. CC-90011 Methylbenzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. CC-90011 Methylbenzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .

HY-A0003S

Lenalidomide-d5 CC-5013-d₅	Isotope-Labeled Compounds Ligands for E3 Ligase Molecular Glues Apoptosis	Inflammation/Immunology Cancer
Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

HY-139504

Gamcemetinib CC-99677	MAPKAPK2 (MK2)	Inflammation/Immunology
Gamcemetinib (CC-99677) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC₅₀=156.3 nM) and cell based assays (EC₅₀=89 nM). Gamcemetinib is extracted from patent WO2020236636, compound 1 .

HY-120188

CC618

PPAR Others

CC618 is a selective peroxisome proliferator-activated receptor (PPARβ/δ) antagonist that exhibits antagonism by covalently binding to PPARβ/δ receptors .

CC618	PPAR	Others
CC618 is a selective peroxisome proliferator-activated receptor (PPARβ/δ) antagonist that exhibits antagonism by covalently binding to PPARβ/δ receptors .

HY-100507

Avadomide 5+ Cited Publications CC 122	E1/E2/E3 Enzyme Apoptosis Molecular Glues	Inflammation/Immunology Cancer
Avadomide (CC 122) is an orally active cereblon modulator. Avadomide modulates cereblon E3 ligase activity and induces apoptosis of diffuse large B-cell lymphoma (DLBCL) cell lines. Avadomide exhibits potent antitumor and immunomodulatory activities .

HY-18012A

Spebrutinib besylate AVL-292 benzenesulfonate; CC-292 besylate	Btk	Cancer
Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a potent inhibitor of Btk kinase activity (IC₅₀<0.5 nM, K_inact/K_i=7.69×10 ⁴ M ^-1s ^-1s) in biochemical assays.

HY-12457

Rachelmycin CC-1065; NSC 298223	Antibiotic DNA/RNA Synthesis	Infection Cancer
Rachelmycin (CC-1065) is an antitumor antibiotic and a DNA-alkylating agent. Rachelmycin has cytotoxic potency that can be used as a cytotoxin to synthesis ADC. Rachelmycin effectively inhibits DNA synthesis. Rachelmycin can be used for cancer and infection research .

HY-145449

CC-885-CH2-PEG1-NH-CH3	ADC Cytotoxin E3 Ligase Ligand-Linker Conjugates	Cancer
CC-885-CH2-PEG1-NH-CH3 is a neoDegrader that can be used in the synthesis of Antibody neoDegrader Conjugate (AnDC) .

HY-RS02018

CC2D1A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CC2D1A Human Pre-designed siRNA Set A contains three designed siRNAs for CC2D1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CC2D1A Human Pre-designed siRNA Set A CC2D1A Human Pre-designed siRNA Set A

HY-RS02019

CC2D2A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CC2D2A Human Pre-designed siRNA Set A contains three designed siRNAs for CC2D2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CC2D2A Human Pre-designed siRNA Set A CC2D2A Human Pre-designed siRNA Set A

HY-145449A

CC-885-CH2-PEG1-NH-CH3 TFA	ADC Cytotoxin E3 Ligase Ligand-Linker Conjugates	Cancer
CC-885-CH2-PEG1-NH-CH3 TFA is a new degrader that can be used to synthesize antibody-based novel degrader conjugated active molecules (AnDC) .

HY-129388A

Pulrodemstat CC-90011; LSD1-IN-7	Histone Demethylase	Cancer
Pulrodemstat (CC-90011) is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC₅₀ of 0.25 nM. Pulrodemstat is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. Pulrodemstat induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .

HY-133073

CCR7 Ligand 1 CCR7-Cmp2105	CCR Ligands for Target Protein for PROTAC	Cancer
CCR7 Ligand 1 (CCR7-Cmp2105) is an allosteric Ligand and antagonist for human CC chemokine receptor 7 (CCR7) with a K_d of 3 nM. CCR7 Ligand 1, thiadiazole-dioxide ligan, suppresses arrestin binding in response to activation by CCL19 with an IC₅₀ of 7.3 μM .

HY-W865379

(S)-Avadomide-d1

SP-3164; CC 122-d₁
Isotope-Labeled Compounds Others

(S)-Avadomide-d₁ (SP-3164; CC 122-d₁) is deuterated labeled (S)-Avadomide-d1 (HY-W865379).

(S)-Avadomide-d1 SP-3164; CC 122-d₁	Isotope-Labeled Compounds	Others
(S)-Avadomide-d₁ (SP-3164; CC 122-d₁) is deuterated labeled (S)-Avadomide-d1 (HY-W865379).

HY-P99496

Cendakimab RPC 4046; ABT 308; CC-93538	Interleukin Related	Inflammation/Immunology
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC₅₀s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .

HY-10984

Pomalidomide 10+ Cited Publications CC-4047	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer
Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.

HY-50081

CCR2-RA-[R] 4 Publications Verification	CCR	Inflammation/Immunology Endocrinology
CCR2-RA-[R] is an allosteric antagonist of the C-C chemokine receptor type 2 (CCR2) with an IC₅₀ of 103 nM.

HY-12085S

Apremilast-d5 CC-10004-d5
Apremilast-d₅ is a deuterium labeled Apremilast. Apremilast is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM[1].

HY-123324

Pomalidomide-5-OH 5-Hydroxy pomalidomide; CC-17368	Ligands for E3 Ligase	Cancer
Pomalidomide-5-OH (5-hydroxy pomalidomide) is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-5-OH can be connected to the ligand for protein by a linker to form PROTAC .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-12457

Rachelmycin CC-1065; NSC 298223	Structural Classification Classification of Application Fields Source classification Disease Research Other Antibiotics Infection Monophenols Microorganisms Antibiotics Phenols Anticancer Disease Research Fields Cancer	Antibiotic DNA/RNA Synthesis
Rachelmycin (CC-1065) is an antitumor antibiotic and a DNA-alkylating agent. Rachelmycin has cytotoxic potency that can be used as a cytotoxin to synthesis ADC. Rachelmycin effectively inhibits DNA synthesis. Rachelmycin can be used for cancer and infection research .

HY-N6622

Tazettine	Structural Classification Alkaloids Source classification Cyrtanthus obliquus (L.f.) Aiton Plants Amaryllidaceae Indole Alkaloids	Others
Tazettine is an alkaloid with low cytotoxicity to mammalian cell lines (CC50 >100 μg/mL) .

HY-141475

Acetoacetyl coenzyme A sodium	Structural Classification Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Acetoacetyl coenzyme A sodium is a central endogenous metabolite. The K_m at pH 7.5 for Acetoacetyl coenzyme A sodium is 1.10 mM. Acetoacetyl coenzyme A sodium can be used for the synthesis of phosphotransbutyrylase (PTB) and poly-3-hydroxybutyrate (PHB) .

HY-N12305

4,5-O-Dicaffeoyl quinic acid methyl ester	Structural Classification Source classification Phenols Polyphenols Amorpha fruticosaL. Plants Compositae	RSV
4,5-O-Dicaffeoyl quinic acid methyl ester (compound 4), a dicaffeoylquinic acid, has potent antiviral activity against respiratory syncytial virus (RSV) with an IC₅₀ of 0.63 μg/mL and a *CC₅₀* of 118.68 μg/mL.

HY-N6048

Lancifodilactone F	Schisandra lancifolia (Rehd. et Wils.) A. C. Smith Triterpenes Structural Classification Terpenoids Source classification Plants Schisandraceae	HIV
Lancifodilactone F (compound 1) can be isolated from the leaves and stems of Schisandra lancifolia. Lancifodilactone F has anti-HIV activity with EC₅₀=20.69 μg/mL. Lancifodilactone F has cytotoxicity against C8166 cells (CC₅₀ >200 μg/mL) .

HY-N2388

Auraptene	other families Classification of Application Fields Source classification Coumarins Phenylpropanoids Plants Disease Research Fields Cancer	MMP
Auraptene is the most abundant naturally occurring geranyloxycoumarin. Auraptene decreases the secretion of matrix metalloproteinase 2 (MMP-2) as well as key inflammatory mediators, including IL-6, IL-8, and chemokine (C-C motif) ligand-5(CCL5) .

HY-N11792

Pedunculosumoside F	Structural Classification Flavonoids Source classification Ophioglossaceae Plants Other Flavonoids Ophioglossum reticulatum L.	Others
Pedunculosumoside F is a homoflavonoid glucoside. Pedunculosumoside F can be isolated from Ophioglossum pedunculosum. Pedunculosumoside F has cytotoxicity against HepG2 22.15 cells with CC₅₀ value of 56.7 μM without anti-HBV activity. While its analogs block HBsAg secretion in HBV-infected HepG2 2.2.15 cells .

HY-N2587

Irigenin	Flavonoids Iridaceae Classification of Application Fields Source classification Phenols Polyphenols Plants Belamcanda chinensis (Linn.) Redouté Disease Research Fields Isoflavones Cancer	Integrin Apoptosis
Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .

HY-N3497

Isochamaejasmin	Structural Classification Flavonoids Thymelaeaceae Stellera chamaejasme Linn. Plants Other Flavonoids	NF-κB DNA/RNA Synthesis Parasite Apoptosis
Isochamaejasmin is a biflavonoid with anti-cancer, antiplasmodial and insecticidal activities. Isochamaejasmin displays a potent NF-κB (NF-κB) activation activity. Isochamaejasmin could cause DNA damage and induce apoptosis via the mitochondrial pathway in AW1 cells . Isochamaejasmin also has a moderate antiplasmodial activity (IC₅₀ of 7.3 μM for *P. falciparum) and relatively low cytotoxicity (CC₅₀* of 29.0 μM) .

HY-B0498

Bindarit 10+ Cited Publications AF2838	Structural Classification Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Plants Umbelliferae Disease Research Fields Endocrinology Echinacea angustifolia DC. Cancer	CCR
Bindarit (AF2838) is a selective inhibitor of the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8, and no effect on other CC and CXC chemokines such as MIP-1α/CCL3, MIP-1β/CCL4, MIP-3/CCL23. Bindarit also has anti-inflammatory activity .

Cat. No.	Product Name	Chemical Structure

HY-A0003S

Lenalidomide-d5

Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

HY-10984S1

Pomalidomide-d3
Pomalidomide-d₃ is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors[1][2].

HY-W865379

(S)-Avadomide-d1

(S)-Avadomide-d₁ (SP-3164; CC 122-d₁) is deuterated labeled (S)-Avadomide-d1 (HY-W865379).

HY-10984S

Pomalidomide-d5
Pomalidomide-d₅ is deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.

HY-10984S2

Pomalidomide-d4
Pomalidomide-d₄ is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors<

HY-12085S2

(Rac)-Apremilast-d5

(Rac)-Apremilast-d₅ is a deuterium labeled (R)-Apremilast. (R)-Apremilast ((R)-CC-10004) is a enantiomer of Apremilast[1].

Cat. No.	Product Name	Application	Reactivity

HY-P81787

Uteroglobin Antibody (YA1532)

Blastokinin; CC10; CC16; CCPBP; CCSP; SCGB1A; UGB; UP1; Uteroglobin
WB, FC Human, Mouse, Rat
HY-P81466

TARC/CCL17 Antibody (YA1211)

TARC; CCL17; SCYA17; C-C motif chemokine 17; C-C motif chemokine 17; Small-inducible cytokine A17; Thymus and activation-regulated chemokine
IHC-P Human
HY-P81628

CCR8 Antibody (YA1373)

CY6; TER1; CCR-8; CKRL1; CDw198; CMKBR8; GPRCY6; CMKBRL2; CC-CKR-8; TER1
FC, ELISA Human
HY-P83257

CC2D1A Antibody (YA3002)

Coiled coil and C2 domain containing 1A; FREUD 1; Freud 1/Aki1; MRT3
WB, ICC/IF, FC Human, Mouse, Rat

HY-P81143

CCR7 Antibody CCR7_HUMAN; BLR 2; BLR2; C C chemokine receptor type 7; C C CKR 7; CC chemokine receptor 7; CC chemokine receptor type 7; CC CKR 7; CCCKR7; CCR 7; CD 197; CD197; CD197 antigen; CDW197; Chemokine C C motif receptor 7; Chemokine C C receptor 7; Chemokine receptor 7-like protein; EBI 1; EBI1; Ebi1h; EBV Induced G Protein Coupled Receptor 1; Epstein Barr virus induced G protein coupled receptor; Epstein Barr virus induced gene 1; EVI 1; EVI1; Lymphocyte Specific G Protein Coupled Peptide Receptor; MGC108519; MIP 3 beta receptor; MIP3 Beta Receptor.	WB; ELISA; IHC-P; IHC-F; Flow-Cyt; ICC; IF	Human, Mouse, Rat(predicted: Dog)
CCR7 Antibody is an unconjugated, approximately 42 kDa, rabbit-derived, anti-CCR7 polyclonal antibody. CCR7 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, ICC, IF expriments in human, mouse, rat, and predicted: dog background without labeling.

HY-P81925

CCL19 Antibody (YA1670) CCL19; ELC; MIP3B; SCYA19; C-C motif chemokine 19; Beta-chemokine exodus-3; CK beta-11; Epstein-Barr virus-induced molecule 1 ligand chemokine; EBI1 ligand chemokine; ELC; Macrophage inflammatory protein 3 beta; MIP-3-beta; Small-inducible	WB, FC	Human

HY-P83178

CCL19 beta Antibody (YA2923) CCL19; ELC; MIP3B; SCYA19; C-C motif chemokine 19; Beta-chemokine exodus-3; CK beta-11; Epstein-Barr virus-induced molecule 1 ligand chemokine; EBI1 ligand chemokine; ELC; Macrophage inflammatory protein 3 beta; MIP-3-beta; Small-inducible	WB	Human

HY-P81171

MCP1 Antibody MCP-1/CCL2; C-C motif chemokine 2; CCL 2; CCL2; CCL2_HUMAN; Chemokine (C C motif) ligand 2; Chemokine C C motif ligand 2; Chemokine CC Motif Ligand 2; GDCF 2; GDCF 2 HC11; GDCF-2; GDCF2; HC11; HSMCR30; HSMCR30; JE; MCAF; MCP 1; MCP-1; MGC9434; Monocyte chemoattractant protein 1; Monocyte chemotactic and activating factor; Monocyte chemotactic protein 1; Monocyte secretory protein JE; SCYA2; Small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig je); Small inducible cytokine A2; Small inducible cytokine subfamily A (Cys Cys), member 2; Small inducible cytokine subfamily A Cys Cys member 2; Small-inducible cytokine A2; SMC CF; SMC-CF; SMCCF.	WB; ELISA; IHC-P; IHC-F; Flow-Cyt; IF	Human, Rat(predicted: Mouse, Dog, Pig, Horse, Rabbit)
MCP1 Antibody is an unconjugated, approximately 11 kDa, rabbit-derived, anti-MCP1 polyclonal antibody. MCP1 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, rat, and predicted: mouse, dog, pig, horse, rabbit background without labeling.

HY-P81323

PP1C gamma Antibody (YA1068) PP 1G; PP-1G; PP1G; PP1G_HUMAN; PP1gamma; PPP 1G; PPP1CC; PPP1CC protein; PPP1G; Protein phosphatase 1 catalytic subunit gamma isoform; Protein phosphatase 1C catalytic subunit; Protein phosphatase 1C subunit; Protein phosphatase 2C gamma isoform; Serine/threonine phosphatase 1 gamma; Serine/threonine protein phosphatase PP1 gamma catalytic subunit; Serine/threonine-protein phosphatase PP1-gamma catalytic subunit.	WB	Human

HY-P82376

Cytochrome P450 24A1 Antibody (YA2121) CYP24A1; CYP24; 1; 25-dihydroxyvitamin D(3) 24-hydroxylase; mitochondrial; 24-OHase; Vitamin D(3) 24-hydroxylase; Cytochrome P450 24A1; Cytochrome P450-CC24	WB	Human

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks